Risk for travellers
The risk of contracting YF is determined by the following factors: travel destination intensity of YF transmission in area to be visited season of travel (most cases in travellers have occurred in the late rainy season to early dry season) duration of travel activities allowing exposure to mosquitoes immunisation status [6] page 3 / 13 Printed:13 Jan 2019
Although ongoing cases and outbreaks of YF occur in Africa and South America, the disease is preventable by vaccination and remains a very rare cause of illness in travellers.
Between August 2016 and 14 March 2017 the European Centre for Disease Prevention and Control (ECDC) reported that four cases of YF had been reported in European travellers who visited YF risk regions in South America [7] . Two YF cases, one fatal, were reported in French travellers in Peru on 10 August 2016. A third case, in a Danish traveller in Bolivia, was confirmed on 13 February 2017 [8] . The fourth case, in a Dutch traveller in Suriname, was reported on 13 March 2017 [9] . None of these four travellers had been vaccinated against YF [7] .
In October 2016, an unvaccinated traveller from USA was diagnosed with yellow fever after returning from the Amazon area of Peru [10] .
In January 2018, the WHO reported a case in an unvaccinated traveller from the Netherlands who had visited the State of Sao Paulo, Brazil [11] . Since this report, a number of other cases have been reported in unvaccinated travellers from Europe, Argentina and Chile who had visited Brazil.
Monitor the Brazil Country Information page for news and outbreaks for updated information.
Prior to these cases, between 1970 and 2015 a total of ten YF cases were reported in unvaccinated travellers from Europe and the United States who visited South America or West Africa [12] .
There have been no confirmed YF cases reported in the UK since 1930, when a laboratory worker contracted YF while working with the virus at the Hospital for Tropical Diseases in London [13] .
Outbreak reports can be helpful when undertaking a risk assessment for travellers. However, it is important to acknowledge the limitations of such reports; case numbers and outbreaks may not accurately represent YF activity and reporting systems and the level of information that is sent to the WHO may differ between countries.
International Health Regulations (2005)
The International Health Regulations (IHR) were revised and adopted by the World Health Assembly in 2005. They were formulated to help prevent the international spread of disease, and in the context of international travel, do so with minimum disruption to trade and travel [1] . Under Annex Other diseases may be designated as above if WHO put in place temporary recommendations as a result of an outbreak being declared a Public Health Emergency of International Concern. Currently YF and polio are the only diseases for which an ICVP may be required for entry into or exit from a country.
As of 11 July 2016, WHO states that the period of validity of the ICVP has changed from 10 years to the duration of the life of the person vaccinated. This applies to all ICVPs for yellow fever vaccination, including certificates already issued, and new or duplicate certificates [14, 15] . WHO states that valid certificates of vaccination presented by arriving travellers cannot be rejected on the grounds that more than ten years have passed since the date vaccination became effective as stated on the certificate; boosters or revaccination cannot be required [14] .
If YF vaccination is contraindicated for medical reasons (including infants under 6 months of age), a Medical Letter of Exemption (MLoE) from vaccination can be issued by an authorised health worker (e.g. in the UK the UKYFVC Responsible Supervising Clinician, a nurse or pharmacist working at that centre, or a licensed health professional otherwise supervising the medical care of the traveller).
Transmission
Jungle primates (e.g. susceptible species of monkey) and humans are the hosts for the YF virus Aedes spp. mosquitoes are adapted to living in an urban (domestic) environment and breed in water collections provided by humans (e.g. vases, tyres and other receptacles); this species is active during daylight hours, and bite from dawn to dusk.
Haemagogous spp. and Sabethes spp. mosquitoes live in the forest canopy in Central and South America. These mosquitoes feed on monkeys; it is unclear if these mosquitoes have a predictable, preferred feeding time [CDC personal communication] . They can descend to ground level when the forest has been disturbed (e.g. during logging or during cultivation), where they may bite humans [17] .
Once infected with the virus, the mosquito remains infectious for life (two to three months).
Generally, mosquito species are most active at times of high rainfall, both in the jungle and urban environments. YF virus can survive very dry conditions in mosquito eggs, which hatch once a water collection is replenished. This can result in YF outbreaks in urban and rural areas, even during the drier months.
Signs and symptoms
YF varies in severity. The infection has an incubation period (time from infected mosquito feeding and symptoms developing) of three to six days. Initial symptoms include myalgia (muscle pain), pyrexia (high temperature), headache, anorexia (lack of appetite), nausea, and vomiting. In many patients there will be improvement in symptoms and gradual recovery three to four days after the onset of symptoms.
Within 24 hours of an apparent recovery, 15 to 25 percent of patients progress to a more serious illness. This takes the form of an acute haemorrhagic fever, in which there may be bleeding from the mouth, eyes, ears, and stomach, pronounced jaundice (yellowing of the skin, from which the disease gets its name), and renal (kidney) damage. The patient develops shock and there is deterioration of major organ function; 20 to 50 percent of patients who develop this form of the disease do not survive [18] . Infection results in lifelong immunity in those who recover.
Diagnosis and treatment
The preliminary diagnosis of YF is based on the patient's clinical features, location and dates of travel, and activities [12] . 
Preventing yellow fever
There are two methods to prevent YF: mosquito control and bite avoidance, and vaccination.
A highly effective live, attenuated (weakened) YF vaccine has been available for more than 70 years [6] . In general, vaccination is recommended for all persons visiting countries where there is a risk of YF virus transmission. Persons who travel to YF risk countries, without the benefit of vaccination should be advised of the risk of contracting YF and the potential for quarantine at the port of entry, depending on the country requirements for vaccination. They should also practise meticulous mosquito bite avoidance.
Vaccine information Country recommendations for YF vaccination
The recommendations for YF vaccination should be reviewed on our Country Information pages.
Vaccine recommendation maps can be used alongside the country information page recommendations. Pregnant women [19] Individual risk assessment should take into account the risk of the disease at the destination versus the potential for adverse events following YF vaccination (which may be greater where certain underlying medical conditions exist). Expert opinion may be advisable.
Indications for use of vaccine
Further information on precaution groups is available in Immunisation against infectious disease, Chapter Ch. 35. Yellow fever and on the Yellow Fever Zone website, provided by NaTHNaC.
Adverse events
The 17D strain virus YF vaccine has been in use for more than 70 years. It is estimated that 500 million doses of the vaccine have been administered worldwide [6] . Reactions to YF vaccine are usually mild and short lived. They include myalgia (muscle pain), headache, and low-grade fever, typically occurring during the first five to ten days post vaccination, and will affect 10-30% of recipients.
Serious adverse events are rare and fall into three main categories: hypersensitivity reactions, vaccine-associated neurologic disease (YEL-AND) and vaccine-associated viscerotropic disease (YEL-AVD).
Hypersensitivity reactions
The vaccine is propagated in chick embryos. The SPC for Stamaril® (the only YF vaccine used in the UK) lists sorbitol and lactose as excipients. Anaphylaxis, because of sensitivity to either egg or other vaccine components, is estimated to occur at an incidence of 1.3 cases/100,000 doses distributed (US data) [21] .
Yellow Fever Vaccine-Associated Neurologic Disease (YEL-AND)
Post-vaccine encephalitis has been recognised as a rare event since the early use of the vaccine.
Cases were reported in very young infants during the 1950s (when there was no age restriction for vaccine administration). In the 1960s, when vaccine use was restricted to babies aged over six months, reduced numbers of post vaccine encephalitis were reported [6] .
Since 2001, a new pattern of neurologic adverse events (undesirable effects on the nervous page 9 / 13 Printed:13 Jan 2019 system) has been recognised [22] [23] [24] [25] . These events have been termed YF vaccine-associated neurologic disease (YEL-AND); Reporting rates are estimated to be 0.8 cases per 100,000 doses distributed (US data) [21] . The rates increased with increasing age (see below) [21] .
The clinical presentation of neurologic events begins two to 56 days following receipt of vaccine (US data) [12] , with fever and headache that can progress to encephalitis (inflammation of the brain), or an autoimmune demyelinating disease (a disorder that can interrupt nerve transmission) with peripheral or central nervous involvement. Most patients will completely recover. Almost all cases have occurred in those receiving the vaccine for the first time with no underlying YF immunity [12] .
Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)
YF vaccine-associated viscerotropic disease (YEL-AVD) is a syndrome of fever and multi-organ failure that resembles severe YF disease; it was first described in 2001 [25] ; over 100 confirmed and suspected cases have been reported worldwide [12] . Three cases have been reported in the United Kingdom, one in 1998 and two in 2000; all the UK cases survived [26] .
One to eighteen days (median four days) following vaccination [12] , patients with YEL-AVD develop fever, malaise, headache, and myalgia that progress to hepatitis (inflammation of the liver), hypotension (low blood pressure), and multi-organ failure. Death has occurred in more than 60 percent of reported cases worldwide [6] . In the US, the case-fatality ratio for all reported YEL-AVD cases is approximately 46 percent [12] .
All reported cases of YEL-AVD have occurred in first-time vaccine recipients [6, 12] .
YEL-AVD has been estimated to be reported in 0.3 cases per 100,000 doses distributed (US data).
The rates increased with increasing age (see below) [21] .
Older travellers
For individuals who are aged 60 years and older, the risk for these serious adverse events increases several fold to approximately 2.2 cases per 100,000 doses distributed for YEL-AND. For YEL-AVD the risk for those who are 60 years and older is 1.2 cases per 100,000 doses distributed and higher for those who are 70 years and older (US data) [21] .
Advancing age (i.e. aged over 60 years) is, therefore a risk factor when considering YF vaccination; vaccine can be offered after careful risk assessment.
Thymus disorder
Additional documented risk factors for serious adverse events following YF vaccination are thymus disorder and thymectomy following a thymus disorder; YF vaccine should never be given to page 10 / 13
